Not available
Quote | Heartbeam Inc. (NASDAQ:BEAT)
Last: | $1.47 |
---|---|
Change Percent: | -2.04% |
Open: | $1.5 |
Close: | $1.47 |
High: | $1.5 |
Low: | $1.4278 |
Volume: | 26,408 |
Last Trade Date Time: | 12/04/2023 03:00:00 am |
News | Heartbeam Inc. (NASDAQ:BEAT)
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for artificial intelligence (“AI”), is reporting...
2023-11-14 19:10:26 ET HeartBeam, Inc. (BEAT) Q3 2023 Earnings Conference Call November 14, 2023 04:30 PM ET Company Participants Branislav Vajdic - Chief Executive Officer & Founder Rob Eno - President Rick Brounstein - Chief Financial Officer Conferen...
Message Board Posts | Heartbeam Inc. (NASDAQ:BEAT)
Subject | By | Source | When |
---|---|---|---|
It's dead | starkd748 | investorshub | 05/10/2023 7:45:27 PM |
$BEAT green to start the afternoon 2.22 up! | budfoxfun | investorshub | 05/09/2023 4:06:34 PM |
$BEAT Funding to Enable Company to Execute on | jedijazz | investorshub | 05/08/2023 3:13:08 PM |
Time for this to show some returns | TopPick | investorshub | 05/07/2023 4:36:32 AM |
Price gaining last up | jedijazz | investorshub | 05/04/2023 5:40:03 PM |
News, Short Squeeze, Breakout and More Instantly...
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for artificial intelligence (“AI”), is reporting...
Strengthens Leadership with Appointments to Executive Team and Boards Publishes Landmark Peer-Reviewed Article, Validating Technology Ongoing Clinical and Regulatory Progress for the HeartBeam AIMIGo ™ VECG Device Management to Host Webcast and Conference Call T...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...